Citations

Showing 10 of 108152 citations.

Faculty Opinions recommendation of Topoisomerase inhibitors and targeted delivery in cancer therapy.
Kaufmann, Scott H.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 18, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.736613832.793565211 Get It

Faculty Opinions recommendation of Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Kaufmann, Scott H.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 18, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.735680777.793565214 Get It

Faculty Opinions recommendation of Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
Kaufmann, Scott H.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 18, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.735680776.793565215 Get It

Faculty Opinions recommendation of NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.
Kaufmann, Scott H.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 18, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.733721497.793565212 Get It

Faculty Opinions recommendation of Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Kaufmann, Scott H.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 18, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.735124171.793565217 Get It

Faculty Opinions recommendation of The essential kinase ATR: ensuring faithful duplication of a challenging genome.
Kaufmann, Scott H.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 18, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.728649753.793565220 Get It

Faculty Opinions recommendation of Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan.
Kaufmann, Scott H.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 18, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.727782010.793565218 Get It

Faculty Opinions recommendation of Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.
Kaufmann, Scott H.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 18, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.727655431.793565216 Get It

Faculty Opinions recommendation of AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells.
Kaufmann, Scott H.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 18, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.727254915.793565221 Get It

Exercise and metformin counteract altered mitochondrial function in the insulin-resistant brain
Ruegsegger, Gregory N. , Vanderboom, Patrick M. , Dasari, Surendra , Klaus, Katherine A. , Kabiraj, Parijat, Lucchinetti, Claudia F. , McCarthy, Christina B. , Nair, K. Sreekumaran

Mayo Clinic

JCI Insight | September 18, 2019 | Volume: 4 | Issue: 18 | Pages: No page available

10.1172/jci.insight.130681 | PMID 31534057 Get It

Insulin resistance associates with increased risk for cognitive decline and dementia; however, the underpinning mechanisms for this increased risk remain to be fully defined. As insulin resistance impairs mitochondrial oxidative metabolism and increases ROS in skeletal muscle, we considered whether similar events occur in the brain, which — like muscle — is rich in insulin receptors and mitochondria. We show that high-fat diet–induced (HFD-induced) brain insulin resistance in mice decreased mitochondrial ATP production rate and oxidative enzyme activities in brain regions rich in insulin receptors. HFD increased ROS emission and reduced antioxidant enzyme activities, with the concurrent accumulation of oxidatively damaged mitochondrial proteins and increased mitochondrial fission. Improvement of insulin sensitivity by both aerobic exercise and metformin ameliorated HFD-induced abnormalities. Moreover, insulin-induced enhancement of ATP production in primary cortical neurons and astrocytes was counteracted by the insulin receptor antagonist S961, demonstrating a direct effect of insulin resistance on brain mitochondria. Further, intranasal S961 administration prevented exercise-induced improvements in ATP production and ROS emission during HFD, supporting that exercise enhances brain mitochondrial function by improving insulin action. These results support that insulin sensitizing by exercise and metformin restores brain mitochondrial function in insulin-resistant states.